Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study-Reference-Cited by-同舟云学术

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study

Published:2014-03-04 Issue:5 Volume:24 Page:734-743
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Tanaka Yoshiya,Yamamoto Kazuhiko,Takeuchi Tsutomu,Yamanaka Hisashi,Ishiguro Naoki,Eguchi Katsumi,Watanabe Akira,Origasa Hideki,Shoji Toshiharu,Miyasaka Nobuyuki,Koike Takao

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/14397595.2014.881709

Reference25 articles.

1. Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation

2. Are biological targets the final goal for rheumatoid arthritis therapy?

3. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

4. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial);Modern Rheumatology;2022-10-05

2. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study;Modern Rheumatology;2022-07-12

3. Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials;International Journal of Molecular Sciences;2019-09-05

4. Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis;Future Science OA;2018-04-01

5. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults;Cochrane Database of Systematic Reviews;2017-09-08